SCHEMBL248524

SCHEMBL248524

O=C(Cl)c1cnco1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27892844 0.80 CHRNA4 (0.44)
SCHEMBL438341 0.78
SCHEMBL2170860 0.78
Benzene SCHEMBL28325923 0.76 CHRNA4 (0.46)
SCHEMBL22361539 0.76
SCHEMBL2413529 0.76
SCHEMBL3114585 0.76
Hydrochloric Acid SCHEMBL30596464 0.76
Hydrochloric Acid SCHEMBL29156121 0.74
Hydrochloric Acid SCHEMBL29290252 0.74 CHRNA4 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243177-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2025-07-31 US disclosed
CN-107021951-B sGC stimulators 赛克里翁治疗有限公司 2020-10-20 CN disclosed
EP-3668845-A1 HERBICIDALLY ACTIVE 3-PHENYL-5-TRIFLUOROMETHYLISOXAZOLINE-5-CARBOXAMIDES OF CYCLOPENTYLCARBOXYLIC ACIDS AND ESTERS Bayer Aktiengesellschaft (DE) 2020-06-24 EP disclosed
US-20190345130-A1 SGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2019-11-14 US disclosed
US-10189809-B2 SGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-29 US disclosed
CN-108707147-A A kind of novel tubulin inhibitor and its application in antitumor drug 桑文军 2018-10-26 CN disclosed
CN-108658963-A A kind of antitumor drug acting on tubulin 桑文军 2018-10-16 CN disclosed
US-20170305878-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-10-26 US disclosed
CN-107021951-A SGC stimulators 铁木医药有限公司 2017-08-08 CN disclosed
EP-3173407-A1 SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2017-05-31 EP disclosed
CN-101018770-A PGD2 receptor antagonists for the treatment of inflammatory diseases MILLENNIUM PHARM INC (US) 2007-08-15 CN disclosed
US-20060148789-A1 Novel diazabicyclic aryl derivatives NEUROSEARCH A/S (DK) 2006-07-06 US disclosed
EP-1599476-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES NEUROSEARCH A/S (DK) 2005-11-30 EP disclosed
WO-2004076453-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES NEUROSEARCH A/S (DK) 2004-09-10 WO disclosed
US-20040097499-A1 Amide, carbamate, and urea derivatives ARNOLD MACKLIN BRIAN (US) 2004-05-20 US disclosed
US-6617351-B1 Amide, carbamate, and urea derivatives ELI LILLY AND COMPANY 2003-09-09 US disclosed
WO-2000006156-A1 AMIDE, CARBAMATE, AND UREA DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed
EP-0976744-A1 Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity ELI LILLY AND COMPANY (US) 2000-02-02 EP disclosed
US-5859008-A Arylalkyl diazinones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-01-12 US disclosed
US-4785012-A OXAZOLE DERIVATIVES CONTAINING ALCOHOLS OR ESTERS SYNTEX CORPORATION (US) 1988-11-15 US disclosed